BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/25/2025 12:09:39 PM | Browse: 20 | Download: 59
 |
Received |
|
2025-03-26 03:30 |
|
Peer-Review Started |
|
2025-04-03 09:09 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-14 10:38 |
|
Revised |
|
2025-04-26 14:31 |
|
Second Decision |
|
2025-06-09 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-09 07:13 |
|
Articles in Press |
|
2025-06-09 07:13 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-06-11 01:43 |
|
Typeset the Manuscript |
|
2025-07-16 01:13 |
|
Publish the Manuscript Online |
|
2025-07-25 12:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Systemic treatment of liver cancer: Current status and future perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Bo Li, Yu-Ting Ning, Nai-Ying Shen, Ben Wang, Han Xiao and Gang Luo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| China-Shaanxi Nuclear Industry Group |
61230303 |
| Shaanxi Nuclear Industry 215 Hospital |
215KYJJ-202214 |
| Jiangxi Provincial Health Commission |
202510800 |
|
| Corresponding Author |
Gang Luo, Department of General Surgery, Jiujiang First People's Hospital, No. 77 Balihu East Road, Balihu New District, Jiujiang 332000, Jiangxi Province, China. luogangxueshu@163.com |
| Key Words |
Primary liver cancer; Systemic therapy; Molecularly targeted drugs; Immunosuppressive therapy; Combination therapy |
| Core Tip |
Primary liver cancer is the malignant tumor with the fifth highest incidence in the world, and hepatocellular carcinoma is the most common among primary liver cancer. Due to the insidious disease onset and rapid progression, most liver cancer patients are diagnosed in the intermediate or advanced stages, and surgery is no longer a viable option. This article summarizes the current challenges faced by the systemic treatment of liver cancer and introduces the prospect of future treatment trends. |
| Publish Date |
2025-07-25 12:09 |
| Citation |
<p>Li CB, Ning YT, Shen NY, Wang B, Xiao H, Luo G. Systemic treatment of liver cancer: Current status and future perspectives. <i>World J Hepatol</i> 2025; 17(7): 107520</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i7/107520.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i7.107520 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
